Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Gains from Investment Securities (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Gains from Investment Securities for 12 consecutive years, with $17000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities changed 0.0% to $17000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $16000.0, a 75.76% decrease, with the full-year FY2024 number at $3.9 million, down 19.49% from a year prior.
  • Gains from Investment Securities was $17000.0 for Q3 2025 at Xtant Medical Holdings, roughly flat from $17000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $17000.0 in Q4 2023 to a low of -$35000.0 in Q4 2024.
  • A 5-year average of $10223.7 and a median of $15000.0 in 2022 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: soared 11100.0% in 2022, then tumbled 305.88% in 2024.
  • Xtant Medical Holdings' Gains from Investment Securities stood at $8000.0 in 2021, then surged by 87.5% to $15000.0 in 2022, then rose by 13.33% to $17000.0 in 2023, then crashed by 305.88% to -$35000.0 in 2024, then skyrocketed by 148.57% to $17000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Gains from Investment Securities are $17000.0 (Q3 2025), $17000.0 (Q2 2025), and $17000.0 (Q1 2025).